The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Single App knock-in mouse models of Alzheimer’s disease
Abstract
Experimental studies of Alzheimer's disease have largely depended on transgenic mice overexpressing amyloid precursor protein (APP). These mice, however, suffer from artificial phenotypes because, in addition to amyloid β peptide (Aβ), they overproduce other APP fragments. We generated knock-in mice that harbor Swedish and Beyreuther/Iberian mutations with and without the Arctic mutation in the APP gene. The mice showed typical Aβ pathology, neuroinflammation and memory impairment in an age-dependent manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We elected to use the AppNL-G-F knock-in mouse model for this study as it expresses App under its endogenous promoter in a physiological manner with regards to both cell type and amount, and avoids the issue of APP overexpression and abnormal expression patterns.”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“AppNL-G-F mice [C57BL/6-App<tm3(NL-G-F)Tcs> (No.RBRC06344)] were provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan [33].”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“we employed APPNLGF knock-in mice that express a humanized and triple-mutated APP in the endogenous App locus to circumvent transgenic mouse artifacts.”
From Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice (2024) · cites this paper as [34]
In the citing paper
“While novel APP knock-in models, such as APPNL, APPNL-F, or APPNL-G-F mice overproduce Aβ1–42 in the absence of potentially confounding APP overexpression [139], these mice still contain one or more independent FAD mutations, which might result in an abnormal Aβ conformation [140].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [139]
In the citing paper
“By 6 months of age, App NL‐G‐F mice exhibit a substantial amyloid plaque burden in the brain”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“These were bred to the App NL‐G‐F AD‐like model to determine responses in the context of amyloid‐driven pathology (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F mice are characterized by progressive amyloid deposition from 2 months to cognitive decline by 6 months (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F knock‐in model, however, has physiological App expression levels, avoiding the overexpression artifacts found in other transgenic models”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“but is strongly biased toward very high Aβ42:40 ratios (~10–100:1) because of the familial mutations”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“In AppNL-G-F mice, which harbor all three mutations, Aβ amyloidosis is aggressive, and neuroinflammation is observed in subcortical structures as well as cortical regions [10–12].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“alternative mouse models have been generated via knock-in (KI) of a humanized Aβ sequences harboring familial AD mutations (Swedish (NL), Beyreuther/Iberian (F), and Arctic (G)) in order to model Aβ amyloidosis without non-physiological overexpression of APP [10].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“To overcome these issues, KI mouse models with familial AD mutations have been generated [10, 24, 31, 32].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“despite overproducing human Aβ40 and Aβ42 in their brains [10, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“These results are consistent with recent studies reporting negligible cognitive deficits and the lack of Aβ plaque formation in AppNL/NL mice (Fig. 6) [10, 11, 13, 14, 24].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“Both models express human APP at physiological levels.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“The AppNL-G-F and AppNL-F show neuropathology and hippocampus-dependent cognitive impairments at 6 or 18 months, respectively.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Our result in female mice is consistent with the cognitive phenotype in the Y maze reported in this genotype25,42.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Human APP knockin (KI) models develop robust Aβ pathology, yet do not exhibit artifacts associated with APP over-expression, such as elevated levels of APP cleavage products (Saito et al., 2014).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These studies all suffer because they exhibit artifacts arising from the over-expression APP (WT or mutant) and in some cases mutant presenilins (Balducci and Forloni, 2011; Saito et al., 2014; Sasaguri et al., 2017).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“Human MAPT knock-in models have also been developed, and these models produce tau pathology, but only very late in the murine life span (~15 months) (Saito et al., 2014; Sakakibara et al., 2018; Sasaguri et al., 2022).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“However, over-expressing APP and presenilin 1 cause effect resulting from the over-expression that are unrelated to the disease process (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These mice develop robust plaque pathology beginning as early as 3 months of age, however they develop little tau pathology and little neurodegeneration (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These patterns of labeling or Aβ and MAPT are consistent with prior studies of APPNL-G-F and P301S MAPT mice (Yoshiyama et al., 2007; Saito et al., 2014; Sasaguri et al., 2017; Apicco et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“As expected,15 22-month-old AppNL-G-F mice had robust AD-related pathology, including amyloid deposition and neuroinflammation (Figures 1C and 1D).”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“As suggested,15,20 App KI mice may model pre-clinical stages of AD, characterized by progressive amyloidosis and gliosis without prominent cognitive deterioration, tau pathology, or neurodegeneration.”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Humanized App knockin (KI) and APP transgenic mouse models mimic certain aspects of AD pathogenesis, including progressive amyloidosis, gliosis, and neuroinflammation, as well as network hyperexcitability and cognitive impairment, albeit to different degrees of severity across models and paradigms.15-27”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Whereas plaque deposition only increases by less than twofold between 9 and 12 months of age, it increases tenfold between 12 and 18 months (Saito et al., 2014).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“By contrast, NHE6 ablation led to glial activation and decreased plaque load in ApoeAPOE4 (Sullivan et al., 1997) and AppNL-F (Saito et al., 2014) double knockin mice.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“The AppNL-F mouse model used in our study develops plaques at 12 months (Saito et al., 2014) in the presence of murine ApoE.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“In AppNL-F mice, plaques can be identified as early as 9 months of age.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“These mice, however, do not show cognitive impairments in spatial learning tests like Morris water maze (Saito et al., 2014) (own unpublished observations).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“We show in a well-studied App knock-in mouse model (Saito et al. , 2014) the gradual establishment of a multicellular co-expressed gene response encompassing 57 Plaque-Induced Genes or PIGs in the microenvironments of amyloid plaques (Figure 5).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“App NL-G-F knock-in (Saito et al., 2014) mice express Swedish (KM670/671NL), Beyreuther/Iberian (I716F), and Arctic (E693G) mutations in the App gene under the endogenous promoter on the C57Bl/6J background.”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“AD mice, in which APP with a humanised Aβ region containing 3 AD-related mutations (APPNL-G-F) is knocked in (49), to avoid artefacts associated with over-expressing APP, were crossed with NG2-DsRed mice in which pericytes express DsRed (19).”
From Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes (2019) · cites this paper as [49]
In the citing paper
“In contrast, knock-in of Swedish and Iberian mutations results in plaque development beginning at 6 months, and gliosis, synaptic alterations and memory impairment from 18 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“Additional knock-in of the Arctic mutation into these mice results in more rapid pathology development including plaque development beginning at 2 months that is more widespread throughout the brain and memory impairment from 6 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“In contrast, initial studies show that more physiological knock-in mouse models develop cognitive impairment many months after plaque development [129], which is more similar to humans.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Self-citationAβ Secretion and Plaque Formation Depend on Autophagy
Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., Iwata, N., Saito, T., & Saido, T. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.042 · Cited by 459
Self-citationSarnyai, Z., Sibille, E. L., Pavlides, C., Fenster, R. J., McEwen, B. S., & Tóth, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14731 · Cited by 396
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,333
Dentoni, G., Naia, L., Portal, B., Leal, N. S., Nilsson, P., Lindskog, M., & Ankarcrona, M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220383 · Cited by 13
Self-citationLinking Social Cognition, Parvalbumin Interneurons, and Oxytocin in Alzheimer’s Disease: An Update
Černotová, D., Hrůzová, K., Levčík, D., Svoboda, J., & Stuchlı́k, A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230333 · Cited by 12
Cross-species comparative hippocampal transcriptomics in Alzheimer’s disease
Bastiani, M. A. D., Bellaver, B., Carello‐Collar, G., Zimmermann, M., Kunach, P., Lima‐Filho, R. A. S., Forner, S., Martini, A. C., Pascoal, T. A., Lourenco, M. V., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108671 · Cited by 13
DNA methylation patterns of FKBP5 regulatory regions in brain and blood of humanized mice and humans
Yusupov, N., Roeh, S., Elliott, L. S., Chang, S., Loganathan, S., Urbina-Treviño, L., Fröhlich, A. S., Sauer, S., Ködel, M., Matosin, N., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02430-x · Cited by 13
Abdelhamid, M., Jung, C., Zhou, C., Inoue, R., Chen, Y., Sento, Y., Hida, H., & Michikawa, M. (2024) · Nutrients · doi:10.3390/nu16040538 · Cited by 13
Palko, S. I., Benoit, M., Yao, A. Y., Mohan, R., & Yan, R. (2024) · Glia · doi:10.1002/glia.24514 · Cited by 12
Bodart‐Santos, V., Ruan, Z., Melvin, B. C., Pandey, I., Ikezu, S., & Ikezu, T. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115025 · Cited by 12
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 14
Bartas, K., Nguyen, M. H., Zhao, W., Hui, M., Nie, Q., & Beier, K. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-10795-4 · Cited by 15
Bouhy, D., Geuens, T., Winter, V. D., Almeida-Souza, L., Katona, I., Weis, J., Hochepied, T., Goossens, S., Haigh, J. J., Janssens, S., et al. (2016) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150144 · Cited by 12
Park, K. H. J., & Barrett, T. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200170 · Cited by 12
Petrache, A. L., Khan, A. A., Nicholson, M. W., Monaco, A., Kuta-Siejkowska, M., Haider, S. M., Hilton, S. T., Jovanovic, J. N., & Ali, A. B. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.568194 · Cited by 14
Byrne, R. A. J., Torvell, M., Daskoulidou, N., Fathalla, D., Kokkali, E., Carpanini, S. M., & Morgan, B. P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02419-5 · Cited by 12
Neuronal Cell Cycle Re-Entry Enhances Neuropathological Features in App NLF Knock-In Mice
Barrett, T., Stangis, K. A., Saito, T., Saido, T. C., & Park, K. H. J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210091 · Cited by 12
Self-citationMizuno, Y., Abolhassani, N., Mazzei, G., Saito, T., Saido, T. C., Yamasaki, R., Kira, J., & Nakabeppu, Y. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.11.009 · Cited by 12
Self-citationKamei, N., Hashimoto, A., Tanaka, E., Murata, K., Yamaguchi, M., Yokoyama, N., Kato, M., Oki, K., Saito, T., Saido, T. C., et al. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01117-6 · Cited by 12
Self-citationOhshima, Y., Taguchi, K., Mizuta, I., Tanaka, M., Tomiyama, T., Kametani, F., Yabe‐Nishimura, C., Mizuno, T., & Tokuda, T. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00511 · Cited by 12
Multidimensional Dynamics of the Proteome in the Neurodegenerative and Aging Mammalian Brain
Andrews, B., Murphy, A. E., Stofella, M., Maslen, S., Almeida-Souza, L., Skehel, M. J., Skene, N., Sobott, F., & Frank, R. A. W. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100192 · Cited by 12
Increased Insoluble Amyloid-β Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice
Salas, I. H., Callaerts-Vegh, Z., D’Hooge, R., Saido, T. C., Dotti, C. G., & De Strooper, B. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180410 · Cited by 12
Self-citationNutma, E., Fancy, N. N., Marzin, M. C., Tsartsalis, S., Muirhead, R. C. J., Falk, I. N., de Bruin, J., Hollaus, D., Pieterman, R., Anink, J. J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1420033/v1 · Cited by 12
Self-citationBhattarai, P., Yılmaz, E., Cakir, E. Ö., Yüceer, H., Lee, A., Ma, Y., Çelikkaya, H., Coşacak, M. İ., Haage, V. C., Wang, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.24.634732 · Cited by 12
Somatostatin slows Aβ plaque deposition in aged APPNL-F/NL-F mice by blocking Aβ aggregation
Williams, D., Yan, B. Q., Wang, H., Negm, L., Sackmann, C., Verkuyl, C. E., Rezai-Stevens, V., Eid, S., Vediya, N., Sato, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29559-z · Cited by 11
Maccioni, R., Travisan, C., Badman, J., Zerial, S., Wagener, A., Andrade‐Talavera, Y., Picciau, F., Grassi, C., Chen, G., Lemoine, L., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102585 · Cited by 11
Self-citationJarero-Basulto, J. J., Gasca-Martínez, Y., Rivera-Cervantes, M. C., Gasca‐Martínez, D., González, N., Beas‐Zárate, C., & Gudiño‐Cabrera, G. (2024) · NeuroSci · doi:10.3390/neurosci5020010 · Cited by 11
RetractedAssociations of amyloid-β oligomers and plaques with neuropathology in the AppNL-G-F mouse
Tang, J., Huang, H. Y. R., Muirhead, R. C. J., Zhou, Y., Li, J., DeFelice, J., Kopanitsa, M. V., Serneels, L., Davey, K., Tilley, B. S., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae218 · Cited by 11
Sánchez-Puebla, L., de Hoz, R., Salobrar‐García, E., Vázquez, A. A., González-Jiménez, M., Ramirez, A. I., Fernández‐Albarral, J. A., Matamoros, J. A., Elvira‐Hurtado, L., Saido, T. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158221 · Cited by 11
Self-citationLin, D., Kaye, S. D., Chen, M., Lyanna, A., Ye, L., Hammond, L. A., & Gao, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107874 · Cited by 12
Zhang, R., Ohshima, M., Brodin, D., Wang, Y., Morancé, A., Schultzberg, M., Chen, G., & Johansson, J. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03161-x · Cited by 11
Tau Accumulation Induces Microglial State Alterations in Alzheimer's Disease Model Mice
Nagata, K., Hashimoto, S., Joho, D., Fujioka, R., Matsuba, Y., Sekiguchi, M., Mihira, N., Motooka, D., Liu, Y., Okuzaki, D., et al. (2024) · eNeuro · doi:10.1523/eneuro.0260-24.2024 · Cited by 11
Self-citationKuriyama, M., Wang, C. F., Nagase, T., Sohma, Y., Kanai, M., Hori, Y., & Tomita, T. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00548 · Cited by 11
Hypercholesterolemia drives microglial dysfunction and weakens response to amyloid plaques
Kaye, S. D., Gold, A., Lin, D., Chen, M., Zhu, J., & Gao, J. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115272 · Cited by 10
ERβ mediates sex-specific protection in the App-NL-G-F mouse model of Alzheimer’s disease
Demetriou, A., Lindqvist, B., Ali, H. G., Shamekh, M. M., Maioli, S., Inzunza, J., Maioli, S., Nilsson, P., & Nalvarte, I. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00711-w · Cited by 11
Self-citationJin, S., Bellier, J., Wells, A. R., Llopis, P. D. L. M. M., Anekal, P. V., Tresback, J. S., Caldarone, B. J., Liu, L., Li, S., Dettmer, U., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70194 · Cited by 11
Yang, S., Miyazaki, H., Wannakul, T., Amo, E., Saido, T. C., Saito, T., Sasaguri, H., Maekawa, M., & Owada, Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05052-8 · Cited by 11
Self-citationWang, D., Chernov, A. V., Lam, R., Wang, H., Li, W., Li, X., Duong, T., Wang, S., & Head, B. P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02258-z · Cited by 11
Singhaarachchi, P. H., Antal, P., Calon, F., Culmsee, C., Delpech, J.-C., Feldotto, M., Geertsema, J., Hoeksema, E. E., Kőrösi, A., Layé, S., et al. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102821 · Cited by 13
Chiasseu, M., Fesharaki‐Zadeh, A., Saito, T., Saido, T. C., & Strittmatter, S. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105059 · Cited by 11
Self-citationNieraad, H., de Bruin, N. M. W. J., Arne, O., Hofmann, M. C. J., Gurke, R., Schmidt, D., Ritter, M., Parnham, M. J., & Geißlinger, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020927 · Cited by 11
Tau-binding protein PRMT8 facilitates vacuole degeneration in the brain
Ishii, A., Matsuba, Y., Mihira, N., Kamano, N., Saito, T., Muramatsu, S., Yokosuka, M., Saido, T. C., & Hashimoto, S. (2022) · The Journal of Biochemistry · doi:10.1093/jb/mvac058 · Cited by 11
Self-citationEx vivo analysis platforms for monitoring amyloid precursor protein cleavage
Kamikubo, Y., Jin, H., Zhou, Y., Niisato, K., Hashimoto, Y., Takasugi, N., & Sakurai, T. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1068990 · Cited by 11
Rahmani, R., Rambarack, N., Singh, J., Constanti, A., & Ali, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914917 · Cited by 11
Mammalian Models in Alzheimer’s Research: An Update
Sharma, H., Chang, K., Hulme, J., & An, S. S. A. (2023) · Cells · doi:10.3390/cells12202459 · Cited by 12
Multi-scale network imaging in a mouse model of amyloidosis
Doostdar, N., Airey, J., Radulescu, C. I., Melgosa-Ecenarro, L., Zabouri, N., Pavlidi, P., Kopanitsa, M. V., Saito, T., Saido, T. C., & Barnes, S. J. (2021) · Cell Calcium · doi:10.1016/j.ceca.2021.102365 · Cited by 11
Self-citationNilsson, P., Sörgjerd, K. M., Kakiya, N., Sasaguri, H., Watamura, N., Johansson, L. E., Shimozawa, M., Tsubuki, S., Zhou, Z., Loera‐Valencia, R., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251392782 · Cited by 11
Self-citationReducing ADAMTS-3 Inhibits Amyloid β Deposition in App Knock-in Mouse
Yamakage, Y., Tsuiji, H., Kohno, T., Ogino, H., Saito, T., Saido, T. C., & Hattori, M. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00899 · Cited by 11
Self-citationJafari, Z., Kolb, B. E., & Mohajerani, M. H. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz089 · Cited by 11
Nutma, E., Fancy, N. N., Weinert, M., Marzin, M. C., Tsartsalis, S., Muirhead, R. C. J., Falk, I. N., de Bruin, J., Hollaus, D., Pieterman, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.11.491453 · Cited by 13
Self-citationHirota, Y., Sakakibara, Y., Takei, K., Nishijima, R., Sekiya, M., & Iijima, K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230121 · Cited by 10
Hall, C. M., Lasli, S., Serwinski, B., Djordjevic, B., Sheridan, G. K., & Moeendarbary, E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1212212 · Cited by 11
Nagayama, T., Yagishita, S., Shibata, M., Furuno, A., Saito, T., Saido, T. C., Wakatsuki, S., & Araki, T. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.03.003 · Cited by 10
Self-citationZhao, N., Wang, J., Huang, S., Zhang, J., Bao, J., Ni, H., Gao, X., & Zhang, C. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01984-z · Cited by 12
Portal, B., Södergren, M., Borrell, T. P. I., Giraud, R., Metzendorf, N. G., Hultqvist, G., Nilsson, P., & Lindskog, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231461 · Cited by 10
Self-citationLee, J., Mizuno, K., Watanabe, H., Lee, I., Tsumita, T., Hida, K., Yawaka, Y., Kitagawa, Y., Hasebe, A., Iimura, T., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03192-7 · Cited by 14
Penning, A., Snoeck, S., Garritsen, O., Tosoni, G., Hof, A., de Boer, F., van Hasenbroek, J., Zhang, L., Thrupp, N., Craessaerts, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-72096-6 · Cited by 11
Sekiya, M., Sakakibara, Y., Hirota, Y., Ito, N., Chikamatsu, S., Takei, K., Nishijima, R., & Iijima, K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106694 · Cited by 10
Sun, K. T., & Mok, S. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00512 · Cited by 12
Microglial Responses to Alzheimer's Disease Pathology: Insights From “Omics” Studies
Reid, A. N., Jayadev, S., & Prater, K. E. (2025) · Glia · doi:10.1002/glia.24666 · Cited by 10
Mishra, R., & Upadhyay, A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05668-y · Cited by 11
Morrone, C. D., Tsang, A. A., & Yu, W. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00877-2 · Cited by 11
Metzendorf, N. G., Sehlin, D., & Hultqvist, G. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1645952 · Cited by 10
Jin, N., Babiloni, C., Drinkenburg, W. H. I. M., Hajós, M., Nygaard, H. B., & Tanila, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210209 · Cited by 10
Holden, S. J., Kundu, P., Torres, E. R. S., Sudhakar, R., Krenik, D., Grygoryev, D., Turker, M. S., & Raber, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.767558 · Cited by 10
Models of cerebral amyloid angiopathy-related intracerebral hemorrhage
Vargas-George, S. A., & Dave, K. R. (2022) · Brain Hemorrhages · doi:10.1016/j.hest.2022.05.001 · Cited by 10
Building in vitro models of the brain to understand the role ofAPOEin Alzheimer’s disease
Pinals, R. L., & Tsai, L. (2022) · Life Science Alliance · doi:10.26508/lsa.202201542 · Cited by 10
Hossain, S. R., Karem, H., Jafari, Z., Kolb, B. E., & Mohajerani, M. H. (2022) · Synapse · doi:10.1002/syn.22257 · Cited by 10
AQP4 Mitigates Chronic Neuropathic Pain-Induced Cognitive Impairment in Mice
Zhang, Y., Feng, J., Ou, C., Zhou, X., & Liao, Y. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114282 · Cited by 10
Distinct effects of SDC3 and FGFRL1 on selective neurodegeneration in AD and PD
Wang, J., Chen, P., Hu, B., Cai, F., Xu, Q., Pan, S., Wu, Y., & Song, W. (2023) · The FASEB Journal · doi:10.1096/fj.202201359r · Cited by 10
An immunological puzzle: The adaptive immune system fuels Alzheimer’s disease pathology
Hoecke, L. V., Castelein, J., Xie, J., Acker, L. V., Imschoot, G. V., Wonterghem, E. V., Vlaeminck, I., Verhaege, D., Claeys, W., Wierda, K. D. B., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.12.026 · Cited by 13
Gut microbiota: A new window for the prevention and treatment of neuropsychiatric disease
Tang, Y., Zhang, Y., Chen, C., Cao, Y., Wang, Q., & Tang, C. (2025) · Journal of Central Nervous System Disease · doi:10.1177/11795735251322450 · Cited by 10
Izumi, H., Kawahata, K., Shinoda, Y., Helmstetter, F. J., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113833 · Cited by 10
Tomizawa, I., Nakagawa, H., Sohma, Y., Kanai, M., Hori, Y., & Tomita, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.945017 · Cited by 10
Expanded targeting scope and enhanced base editing efficiency in rabbit using optimized xCas9(3.7)
Liu, Z., Chen, M., Shan, H., Chen, S., Xu, Y., Song, Y., Zhang, Q., Yuan, H., Ouyang, H., Li, Z., et al. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03110-8 · Cited by 10
Analysis of Taste Sensitivities in App Knock-In Mouse Model of Alzheimer’s Disease
Narukawa, M., Takahashi, S., Saito, T., Saido, T. C., & Misaka, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200284 · Cited by 10
Self-citationChronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition
Blume, T., Deussing, M., Biechele, G., Peters, F., Zott, B., Schmidt, C., Franzmeier, N., Wind, K., Eckenweber, F., Sacher, C., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.854031 · Cited by 10
Iwata, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x1601171214093100 · Cited by 10
Self-citationEffects of Probiotics on Colitis-Induced Exacerbation of Alzheimer’s Disease in AppNL-G-F Mice
Sahu, B., Johnson, L. M., Sohrabi, M., Usatii, A. A., Craig, R. M. J., Kaelberer, J. B., Chandrasekaran, S. P., Kaur, H., Nookala, S., & Combs, C. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411551 · Cited by 9
Preventive effect of propolis on cognitive decline in Alzheimer’s disease model mice
Inagaki, R., Yamakuni, T., Saito, T., Saido, T. C., & Moriguchi, S. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.03.002 · Cited by 9
Self-citationModeling of age-related neurological disease: utility of zebrafish
Kanoh, T., Mizoguchi, T., Tonoki, A., & Itoh, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1399098 · Cited by 9
Using in vivo intact structure for system-wide quantitative analysis of changes in proteins
Son, A., Kim, H., Diedrich, J. K., Bamberger, C., McClatchy, D. B., Lipton, S. A., & Yates, J. R. (2024) · Nature Communications · doi:10.1038/s41467-024-53582-x · Cited by 9
Adak, S., Singh, S., Jain, R., Tiwari, A., Singh, B., Kumar, S., Dadhwal, A., Chakroborty, A., Sharma, A. K., Singh, R. P., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1646551 · Cited by 12
Zhang, Z., Li, S., Xu, L., Xiao, S., Li, Y., Huang, J., Huang, J., Zuo, Y., Wen, W., Dai, Q., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02261-9 · Cited by 9
Tsuda, L., Omata, Y., Yamasaki, Y., Minami, R., & Lim, Y. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx346 · Cited by 9
Murakami, K., Sakaguchi, Y., Taniwa, K., Izuo, N., Hanaki, M., Kawase, T., Hirose, K., Shimizu, T., & Irie, K. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00194b · Cited by 9
Cognitive decline in diabetic mice predisposed to Alzheimer’s disease is greater than in wild type
Carús-Cadavieco, M., Berenguer, I., Canelo, A. M., Serrano-Lope, M. A., la Fuente, S. G., Aguado, B., Fernández‐Rodrigo, A., Saido, T. C., Frank, A., Venero, C., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201789 · Cited by 9
Self-citationInayat, S., McAllister, B. B., Chang, H., Lacoursiere, S. G., Whishaw, I. Q., Sutherland, R. J., & Mohajerani, M. H. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.06.002 · Cited by 9
Papazoglou, A., Henseler, C., Weickhardt, S., Teipelke, J., Παπάζογλου, Π., Daubner, J., Schiffer, T., Krings, D., Broich, K., Hescheler, J., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296959 · Cited by 9
Huang, H., Sharoar, M. G., Pathoulas, J., Fan, L., He, W., Xiang, R., & Yan, R. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167086 · Cited by 9
Development of Triphenylmethane Dyes for In Vivo Fluorescence Imaging of Aβ Oligomers
Nagashima, K., Watanabe, H., Akasaka, T., & Ono, M. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00053 · Cited by 9
Wang, N., Parsons, T. M., Ren, Y., Pan, Y., Kurti, A., Starling, S. C., Muolokwu, C. E., Singh, J., & Kanekiyo, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39607 · Cited by 9
The Icelandic Mutation (APP-A673T) Is Protective against Amyloid Pathology In Vivo
Shimohama, S., Fujioka, R., Mihira, N., Sekiguchi, M., Sartori, L., Joho, D., Saito, T., Saido, T. C., Nakahara, J., Hino, T., et al. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.0223-24.2024 · Cited by 9
Self-citationKreiner, G. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.09.006 · Cited by 9
Hamaguchi, T., Tsutsui‐Kimura, I., Mimura, M., Saito, T., Saido, T. C., & Tanaka, K. F. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104470 · Cited by 9
Self-citationTraffic noise exposure, cognitive decline, and amyloid‐beta pathology in an AD mouse model
Karem, H., Mehla, J., Kolb, B. E., & Mohajerani, M. H. (2020) · Synapse · doi:10.1002/syn.22192 · Cited by 10
Li, M., Tang, X., You, W., Wang, Y., Chen, Y., Liu, Y., Yuan, H., Gao, C., Chen, X., Xiao, Z., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.011 · Cited by 9
Minamisawa, M., Sato, Y., Ishiguro, E., Taniai, T., Sakamoto, T., Kawai, G., Saito, T., & Saido, T. C. (2021) · Life · doi:10.3390/life12010034 · Cited by 9
Self-citationChino, K., Izuo, N., Noike, H., Uno, K., Kuboyama, T., Tohda, C., Muramatsu, S., & Nitta, A. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03649-2 · Cited by 9
β-secretase inhibition prevents structural spine plasticity deficits in AppNL-G-F mice
Blume, T., Filser, S., Sgobio, C., Peters, F., Neumann, U., Shimshek, D. R., Saito, T., Saido, T. C., Brendel, M., & Herms, J. W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.909586 · Cited by 10
Self-citationHata, S., Kikuchi, K., Kano, K., Saito, H., Sobu, Y., Kinoshita, S., Saito, T., Saido, T. C., Sano, Y., Taru, H., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15490 · Cited by 9
Self-citationA Human Embryonic Stem Cell Model of Aβ-Dependent Chronic Progressive Neurodegeneration
Ubina, T., Magallanes, M., Srivastava, S., Warden, C., Yee, J., & Salvaterra, P. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01007 · Cited by 9
Aβ43 levels determine the onset of pathological amyloid deposition
Tambini, M. D., Yin, T., Yesiltepe, M., Breuillaud, L., Zehntner, S. P., d'Abramo, C., Giliberto, L., & D'Adamio, L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104868 · Cited by 8
Metadata
- Authors
- Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C.
- Affiliations
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Saido, Takaomi C
- Venue
- Nature Neuroscience
- Published
- 2014-04-13
- Volume
- 17
- Issue
- 5
- Pages
- 661-663
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2090620788
- Cited by
- 1,366
- References
- 26
- Citations by year
- 2026: 159 · 2025: 164 · 2024: 209 · 2023: 167 · 2022: 157 · 2021: 155 · 2020: 92 · 2019: 73 · 2018: 64 · 2017: 49 · 2016: 37 · 2015: 24 · 2014: 13
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23680039, 26290019)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, knock-in mice, amyloid precursor protein, APP mutations, Swedish mutation, Arctic mutation, amyloid-beta pathology, neuroinflammation, memory impairment, age-dependent phenotype
- MeSH terms
- Age Factors, Alzheimer Disease, Analysis of Variance, Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Maze Learning, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
